<DOC>
	<DOCNO>NCT00043394</DOCNO>
	<brief_summary>To determine safety efficacy CPG 7909 Injection give Herceptin patient metastatic breast cancer .</brief_summary>
	<brief_title>CPG 7909 Plus Herceptin速 In Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm breast cancer metastases Tumor overexpression HER2 document either FISHpositive HER2/neu 3+ confirm immunohistochemistry Patients may three prior chemotherapy regimens metastatic disease , may give combination Herceptin速 may discontinue due toxicity . In addition , patient may adjuvant chemotherapy . Phase II : Must measurable disease RECIST criterion ( define section 8 ) least one lesion accurately measure least one dimension ( long diameter record ) &gt; 20 mm conventional technique , &gt; 10 mm spiral CT scan Any prior therapy anthracycline + Herceptin速 concurrently Significant cardiovascular disease ( e.g. , NYHA class 3 congestive heart failure , myocardial infarction within past 6 month , unstable angina ; coronary angioplasty within past 6 month , uncontrolled atrial ventricular cardiac arrhythmia ) leave ventricular ejection fraction &lt; 50 % Preexisting autoimmune antibodymediated disease include limited : systemic lupus erythematosus , rheumatoid arthritis , multiple sclerosis , Sjogren 's syndrome , autoimmune thrombocytopenia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>CpG 7909 subcutaneous injection combination Herceptin速 metastatic breast cancer .</keyword>
</DOC>